knowledge -WSS

knowledge

author：hotspot 2025-08-30 19:15:21 - browse：78277

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： ‘The Bear’ and hospitality in hospitals

hotspot

WSS

Big Tobacco's 'harm reduction': Is it for real, or a sham?

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Ohioans vote in high

Former Georgia lieutenant governor says he received grand jury subpoena

Anxious about a speech? A startup wants you to pop a minty cardiac drug

focus

knowledge

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

The painfully weak evidence on taking collagen to treat arthritis

United colonoscopy coverage change 'may cost lives,' doctors say

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

State Dept. review finds Biden bears some blame for Afghanistan failures

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

The cancer drug shortage isn’t new — and neither are the solutions

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

The high cost of giving birth even with insurance

Arc Institute generative AI designs new CRISPR systems

focus

Wearables generate powerful data but its not useful to doctors, yet

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Venture capitalist Bob Kocher on the state of digital health

Lessons Learned: This is why you network to find that industry job you want

Discs beat pads, tampons for heavy menstrual flow, new study shows

Former Georgia lieutenant governor says he received grand jury subpoena

Wikipedia

hotspot

explore

knowledge